In this issue:
Adagrasib for KRASG12C-mutated NSCLC
Ramucirumab + pembrolizumab in advanced NSCLC after immunotherapy
Active symptom control ± vinorelbine in relapsed malignant pleural mesothelioma
TP53 comutations and immunological microenvironment in lung cancer with EGFR exon 20 insertions
Durvalumab + chemoradiotherapy for limited-stage SCLC
Taminadenant ± spartalizumab for advanced NSCLC
Continuing pembrolizumab with chemotherapy after progression on anti-PD-(L)1 alone in advanced NSCLC
Adding bevacizumab to atezolizumab after progression in pretreated NSCLC
ICI pneumonitis in real-world lung cancer patients
Health-related QOL in resected EGFR-mutatedNSCLC treated with adjuvant osimertinib
Please login below to download this issue (PDF)